Pfizer tracks safety of prostate cancer drug in Real-World use
NCT ID NCT06733337
Summary
This study is monitoring the safety of the drug Talzenna in men with advanced prostate cancer that has a specific genetic change (BRCA mutation), has spread, and no longer responds to standard hormone therapy. All participants will receive Talzenna as prescribed by their doctor. Researchers will follow patients for up to one year to track any side effects, focusing on specific risks like blood cell problems and lung issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Japan
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.